[1] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in china:a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822.
[2] Zhang L, Zuo L, Wang F, et al. Cardiovascular disease in early stages of chronic kidney disease in a Chinese population[J]. J Am Soc Nephrol, 2006, 17: 2617-2621.
[3] Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk B, et al. Markers of increased atherosclerotic risk in patients with chronic kidney disease:a preliminary study[J]. Lipids Health Dis, 2016, 15: 22.
[4] Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system[J]. Circulation, 2007 ,116(1): 85-97.
[5] Razzaque MS. FGF23, klotho and vitamin D interactions What have we learned from in vivo mouse genetics studies[J]. Adv Exp Med Biol, 2012, 728: 84-91.
[6] ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23[J]. Nat Genet, 2000 , 26(3): 345-348.
[7] Shimada T, Mizutani S, Muto T , et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia[J]. Proc Natl Acad Sci USA, 2001, 98(11): 6500-6505.
[8] Perwad F, Zhang MY, Tenenhouse HS, et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-lalpha-hydroxylase expression in vitro[J]. Am J Physiol Renal Physiol, 2007, 293(5): 1577-1583.
[9] Shimada T, Hasegawa H, Yamazaki Y, et a1. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis[J]. J Bone Miner Res, 2004, 19(3): 429-435.
[10] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,classlfication,and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1): 1-266.
[11] Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate [J]. Ann Intern Med, 2006, 145(4): 247-254.
[12] Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology[J]. J Am Soc Echocardiogr, 2005, 18(12): 1440-1463.
[13] Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings[J]. Am J Cardiol, 1986, 57(6): 450-458.
[14] Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kindey disease[J]. J Am Soc Nephrol, 2005, 16(7): 2205-2215.
[15] Quarles LD. Role of FGF23 in vatamin D and phosphate metabolism: Implications in chronic kidney disease [J]. Exp Cell Res, 2012, 318(9): 1040-1048.
[16] Kurosu H, Ogawa Y, Miyoshi M,et al. Regulation of fibroblast growth factor-23 signaling by klotho[J]. J Biol Chem, 2006, 281(10):6120-6123.
[17] Zununi Vahed S, Nikasa P, Ardalan M. Klotho and Renal Fibrosis[J]. Nephrourol Mon, 2013, 5(5): 946-948.
[18] Bing Dai, Valentin David, Aline Martin, et a1. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model[J]. PLoS One, 2012, 7(9): 44161.
[19] Manqhat P, Fraser WD, Wierzbicki AS, et al.Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease[J]. Osteoporos Int, 2010, 21(11): 1853-1861.
[20] 李柱宏, 万静芳, 张志诚, 等. 慢性肾脏疾病肾功能代偿期患者外周血FGF23水平的变化及其意义[J]. 中华临床医师杂志(电子版), 2013, 7(6): 2318-2322.
[21] Faul C, Amaral AP, Oskouei B, et al. FGF 23 induces left ventricular hipertrophy[J]. J Clin Invest, 2011, 121(11): 4393-4408.
[22] Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD[J]. J Am Soc Nephrol, 2014, 25(2): 349-360.
[23] Itoh N,Ohta H.PathophysioIogical roles of FGF signaling in the heart[J]. Front Physiol, 2013, 4: 247.
[24] Huqhes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues[J]. J Histochem Cytochem, 1997, 45(7): 1005-1019.
[25] Liu L, Pasumarthi KB, Padua RR, et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor[J]. Am J Physiol, 1995, 268(5 Pt 2):H1927-1938.
[26] Leifheit-Nestler M, Gro?e Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease[J]. Nephrol Dial Transplant, 2016, 31(7): 1088-1099.
[27] Leifheit-Nestler M, Grabner A, Hermann L, et al. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats[J]. Nephrol Dial Transplant, 2017, 32(9): 1493-1503.
[28] Arnlov J, Carlsson AC Sundstrom J et a1. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology[J]. Clin J Am Soc Nephrol, 2013, 8(5): 781-786.
[29] Dai B, David V, Martin A, et a1. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model[J]. PLoS One, 2012, 7(9):44161.
[30] Liu S, Tang W, Zhou J, et a1. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D[J]. J Am Soc Nephrol, 2006, 17(5):1305-1315.
